Adaptimmune Reports First Quarter Financial Results and Business Update
We are tackling cancer with our affinity enhanced t-cell therapies. They work with the body’s immune system to improve the detection and targeting of cancer cells.
Quarter Ended Mar 31, 2021
Revenue for the first quarter ended March 31, 2021 was $0.4 million.
As of March 31, 2021, Adaptimmune had cash and cash equivalents of $32.4 million and Total Liquidity of $317.9 million.
For Fiscal Year Ending Dec 31, 2020
For complete information regarding our financials, see our periodic filings
Stay informed and receive company updates straight to your inbox.
Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for people with cancer. The Company’s unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T‑cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors.
Responses in six solid tumor indications demonstrate SPEAR T-cell potential to treat cancer.
The Company aims to launch ADP‑A2M4 for sarcoma in 2022.
Following our June 2020 public offering, we raised approximately $243 million to advance the development of our therapies into and through clinical trials as well as for other general corporate purposes.
As of June 4, 2020
✔ Responses in solid tumors outside sarcoma
✔ Co-development and co-commercialization agreement with Astellas
✔ Data update from allogeneic program at scientific meeting
✔ Full presentation of ADP-A2M4 Phase 1 trial
*at medical conferences
As of June 18, 2020 • June 2020 Corporate Deck
Adaptimmune’s affinity enhanced T-cell therapies work with the immune system to improve detection and targeting of cancer cells, resulting in the destruction of those cancer cells. We believe that the unique potential of immunotherapy will revolutionize the treatment of oncology in the future and that we are at the forefront of immunotherapy developmentView Pipeline